CRINETICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 TRIAL EVALUATING CRN09682 FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND OTHER SOMATOSTATIN RECEPTOR 2-EXPRESSING TUMORS

Reuters · 2d ago

Please log in to view news